Between 1980 and 2008, the age-standardized mean global body mass index (BMI) increased by 0.4–0.5 kg/m2 per decade in men and women, and worldwide obesity more than doubled. Obesity, and particularly morbid obesity (BMI ≥ 40) is known as a strong risk factor for several diseases and premature death.
Bariatric surgery is the only evidence-based treatment of morbid obesity with proven, sustained weight loss and improvement in comorbidities.[3–5] Laparoscopic sleeve gastrectomy (LSG) was introduced as the first stage in a two-staged bariatric surgical approach on super-obese or high-risk patients, but has now gained acceptance as a stand-alone bariatric procedure.[7–11] Physiologically it is an attractive procedure because it reduces the gastric volume while preserving the continuity of the gastrointestinal tract. Data on complications and weight loss after LSG have been increasingly published in the surgical literature, but data for the effects on comorbidities and micronutrients should be further explored.[12,13]
Our bariatric surgical program started in 2001 with open Biliopancreatic diversion with duodenal switch (BPDDS), and LSG as a stand-alone procedure was started in May 2007. We had no experience with laparoscopic bariatric surgery prior to May 2007, and this prospective study reviews our first patients focusing on procedure complications, comorbidity resolution and changes in biochemical variables at 12 and 24 months postoperatively.
BMC Surg. 2014;14(8) © 2014 BioMed Central, Ltd.
© 1999-2006 BioMed Central Ltd